Navigation Links
ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results
Date:11/2/2010

IRVINE, Calif., Nov. 2, 2010 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today reported financial results for the quarter ended September 30, 2010.  Third quarter 2010 net revenues were $42.0 million, an increase of 31% from the third quarter of 2009.  Excluding the recognition of one-time license revenue in the third quarter of 2009, net product revenues increased 44%.  Net loss for the third quarter ended September 30, 2010, was $23.5 million, or $0.70 per diluted share, compared to a net loss of $917,000, or $0.03 per diluted share, for the third quarter ended September 30, 2009.  Excluding non-cash warrant valuation adjustments and license revenue, net income for the third quarter of 2010 was $2.8 million, or $0.08 per diluted share compared to a loss of $0.4 million, or $0.01 per diluted share in the third quarter of 2009.

"These are exciting times at ISTA.  After a strong first half of the year, the third quarter demonstrates that we are on track for an equally strong second half.  Not only are we posting revenue growth for all four products and delivering improved operating profitability, we are achieving key new product pipeline milestones," stated Vicente Anido, Jr., Ph.D., President and Chief Executive Officer of ISTA.  "Most recently, we announced the U.S. Food and Drug Administration (FDA) approved BROMDAY™ (bromfenac ophthalmic solution) 0.09% (formerly known as XiDay), our once-daily formulation of bromfenac sodium ophthalmic solution for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.  We believe the introduction of the first and only once-daily non-steroidal anti-inflammatory (NSAID) prescription eye drop will help with treatment compliance and benefit patients recovering from cataract surgery.  Our sales forc
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. DUSA Pharmaceuticals, Inc.® to Host Third Quarter 2010 Corporate Highlights and Financial Results Conference Call
2. Access Pharmaceuticals Awarded $1.5 Million in Section 48D Grants
3. Anadys Pharmaceuticals to Report Third Quarter 2010 Financial Results
4. Alder Biopharmaceuticals Appoints Bruce Montgomery to Board of Directors
5. Alexza Pharmaceuticals to Announce 2010 Third Quarter Financial Results on November 9, 2010
6. AVANIR Pharmaceuticals Invites Investors to Conference Call Regarding FDA Approval of NUEDEXTA™ on Monday November 1, 2010
7. AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
8. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2010 Financial Results on November 5, 2010
9. Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2010 Financial Results
10. VIDEO from thenewsmarket.com and Roche Pharmaceuticals: MabThera Approved in Europe for First Line Maintenance Treatment of Follicular Lymphoma, a Common Type of Blood Cancer
11. MAP Pharmaceuticals to Present Data Showing Low Migraine Recurrence Rates With LEVADEX™ in FREEDOM-301 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Mettler-Toledo International Inc. (NYSE: MTD ) today announced ... highlights: , Sales in local currency increased ... Reported sales decreased 4% as currency reduced sales growth ... per diluted share as reported (EPS) were $2.73, compared ... $2.80 , an increase of 9% over the ...
(Date:7/30/2015)... , July 30, 2015 IRIDEX Corporation (NASDAQ: ... its second quarter 2015 financial results after the market ... conjunction with the release, the Company will host a ... p.m. Eastern Time on Thursday, August 6, ... and other business developments. Interested parties may ...
(Date:7/30/2015)... 30, 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... manufacturer of the t:slim® and t:flex™ Insulin Pumps, ... Development Agreements with Dexcom, Inc. to allow the ... the Dexcom G5 and G6 continuous glucose monitoring ... pump platform with Dexcom,s future CGM systems is ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3
... Aug. 30, 2011 Luminex Corporation (Nasdaq: ... two upcoming investment conferences, the Morgan Stanley Global Healthcare ... scheduled to take place in New York City. ... Patrick J. Balthrop, president and chief executive officer, will ...
... REDWOOD CITY, Calif., Aug. 30, 2011 Pearl ... randomized, double-blind, Phase 2b, dose-ranging study of its ... a long-acting beta-2 agonist (LABA) compared to placebo ... All doses of FF MDI tested produced highly ...
Cached Medicine Technology:Luminex Corporation to Present at Upcoming Investment Conferences In September 2Pearl Therapeutics Announces Positive Results for Phase 2b Dose-Ranging Study of Formoterol MDI 2Pearl Therapeutics Announces Positive Results for Phase 2b Dose-Ranging Study of Formoterol MDI 3
(Date:8/1/2015)... ... ... Tina Wilcoxson, owner of Freeport Maine’s Royal River Natural Foods, was named one ... Federation, the largest retail trade association in the world, for her “advocacy and engagement” ... named as such. According to the NRF’s website, Retail Champions are “Main Street business ...
(Date:8/1/2015)... CT (PRWEB) , ... August 01, 2015 , ... ... Point Partners I, L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy & ... it into its portfolio of state-of-the-art clinics. , “Our acquisition of Premier Physical ...
(Date:8/1/2015)... ... ... Lume Wellness creators Alex, Robert, and Sam have announced update 3.0.1 to this ... The app is designed to track various metrics of wellness, including physical activity, diet, ... and use this information for positive behavior modification. Lume Wellness keeps track of both ...
(Date:8/1/2015)... ... 2015 , ... “ reTXT ” was featured on NewsWatch as part of ... the market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and ... edit and delete any message including ones already sent. , While text messaging has ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... High Times magazine. What are the STASH awards? The Significant Technological Achievements ... by the cannabis-cultivation community as well as tried-and-true products that have stood the ...
Breaking Medicine News(10 mins):Health News:Local Retail Advocate Wins National Recognition 2Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2
... tablets such as pain killers are packaged today in ... some form of desiccant to protect the contents against ... the contents from rattling around. , However, such caps ... two hands to manipulate. Customers and,suppliers of vitamin pills ...
... an army of plant viruses to their cause, materials ... (NIST) have identified a small biomolecule that binds specifically ... bodythe calcium compound that is the basic building block ... the new molecule can be a highly discriminating probe ...
... American Tradition -- What,s the Problem?, ... Seniors Ask, WASHINGTON, ... the sight of seniors attending a,seminar about Medicare Advantage-Part D, asking questions, and ... some federal regulators,get their way., A proposed prohibition on free meals is ...
... ... Troops, BOSTON, July ... the most underserved and,at-risk groups in our country, today announced the launch ... those soldiers,who have been wounded in conflict in the Middle East and ...
... Hot Water & Healthy Living, reviews scientific findings about warm-water ... ... For those who have,wondered how warm water makes them feel so good, ... Swimming Pool Foundation,(NSPF), "Hot Water & Healthy Living" provides a thorough review ...
... ... Care, BREA, ... owners are recalculating their,household budgets. The average pet owner typically budgets for ... as,preventive health checks and vaccinations. However, most assume that their,pet,s youth or ...
Cached Medicine News:Health News:Integrated tube cap design simplifies access to medication 2Health News:Toothpick: New molecular tag IDs bone and tooth minerals 2Health News:Proposed Medicare Regulations Threaten to End Millions of Free Meals Offered to Seniors During Education Seminars 2Health News:Purple Dog Tag Launches; Provides Hope and Healing to Thousands of US Servicemen & Veterans 2Health News:New Book Reveals Warm Water Benefits for Heart, Lungs and Mind 2Health News:Veterinary Pet Insurance Reports Pet Emergencies a Costly Reality 2Health News:Veterinary Pet Insurance Reports Pet Emergencies a Costly Reality 3Health News:Veterinary Pet Insurance Reports Pet Emergencies a Costly Reality 4
Amylase (EPS-G7, kinetics), Wavelength: 405 nm. Linear range; 5-1500 IU/L....
g-GT Liquid Reagent (Kinetic Method). Wavelength: 405 nm. Linear range: 0-200 U/mL. Prepare Working Reagent in the ratio of 5 parts R1 to 1 part of R2, (i.e., 50 mL R1 and 10 mL R2)....
Intended for the quantitative determination of calcium in serum. Endpoint Reaction. Reaction complete within one minute, color developed is stable for 30 minutes. Wavelength: 570 nm. Linearity: 16 mg...
... for the quantitative determination of ... or plasma. Two vials, dry ... must be purchased separately for ... reaction. Wavelength: 340 nm. Linearity: ...
Medicine Products: